Genomic test could help predict aggressive disease in men newly diagnosed with prostate cancer

An analysis of patient data from across Michigan found scores from the Decipher Biopsy test independently aligned with outcomes.

9:05 AM

Author | Ian Demsky

teal microscopic cell prostate cancer
Prostate cancer cells. Annie Cavanagh (CC BY-NC 4.0)

After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.

And identifying which patients will benefit from more immediate and aggressive treatment isn't always clear.

A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan, however, found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of cancer progression.

"We have long needed better tools to reduce the uncertainty of these initial treatment decisions," said study first author
Randy Vince, Jr., M.D., M.S.
, an oncology fellow at U-M.

Veracyte, the company that makes the tests, did not sponsor the study or play a role in the analysis.

Between February 2015 and October 2019, 855 patients participating in the state Michigan Urological Surgery Improvement Collaborative registry underwent testing with the Decipher Biopsy test after being diagnosed with prostate cancer —  one of the first real-world, observational studies of a commercially available genomic test designed to aid in decision-making after an initial diagnosis.

The research team found the data supported the clinical utility of the Decipher Biopsy test, according to findings published in Prostate Cancer and Prostatic Diseases.

The analysis found men with a high Decipher score who were placed on active surveillance had a shorter time before active treatment was needed, Vince said. And for those who underwent surgery to remove the prostate gland, high scores were associated with shorter time until their prostate-specific antigen (PSA) levels went up again or when they were put on anti-androgen therapy.

Meanwhile, G-MAJOR, an ongoing clinical trial led by study senior author Todd Morgan, M.D., a member of the U-M Rogel Cancer Center who heads the division of urologic oncology at U-M, is evaluating the use of Decipher and other similar molecular classifying tests in lower-risk prostate cancer to more fully evaluate their clinical utility. The trial is also being led by study co-author Daniel Spratt, M.D., formerly of U-M and now chair of the Department of Radiation Oncology at Case Western Reserve University.

The statewide collaborative, known as MUSIC, is managed by the MUSIC Coordinating Center, which is housed at U-M. Support for MUSIC is provided by Blue Cross and Blue Shield of Michigan.

Disclosures: One of the study authors has received research funding from Decipher Biosciences. Several authors also reported receiving funding and fees from pharmaceutical companies. One has equity interest in LynxDX, a U-M startup that is developing a urine-based assay for prostate cancer.

Study Cited: "Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative," Prostate Cancer and Prostatic Diseases.
DOI: 10.1038/s41391-021-00428-y


More Articles About:

Lab Notes Cancer: Help, Diagnosis & Treatment All Research Topics Prostate Cancer Community Health Wellness and Prevention Cancer: Cancer Types
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Man sits in a medical exam room looking at caregiver whose back is to camera and looks toward a computer screen.
Health Lab

Updated prostate cancer screening guidelines emphasize benefits of early detection

New guidelines for prostate cancer screening focus on early detection and individual risk.
Close up of woman's mouth as cheek swab is performed, with Q tip held in a green medical gloved hand.
Health Lab

Are you at risk of a genetic disease? Guidelines for testing should be updated, experts say

Genetic counselor calls for updated guidelines on testing for diseases like Huntington's and Alzheimer's diseases.
Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.